MANKIND Mankind Pharma Q3 FY26 results (Oct–Dec 2025) and concall
Mankind Pharma delivered a robust Q3 FY26, with strong revenue growth across domestic and international segments, driven by chronic therapies and the BSV portfolio. Despite a dip in adjusted EBITDA margin due to R&D and employee costs, the company maintained healthy profitability and significantly improved its net debt position. Management highlighted ongoing strategic transformations and expressed confidence in future growth, particularly in chronic and OTC segments, while addressing challenges in acute and anti-infective categories.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 11.5%, net profit up 7.5% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|
| Revenue | 3,199 | 3,079 | 3,570 | 3,697 | 3,567 +12% |
| EBITDA | 816 | 683 | 847 | 921 | 919 +13% |
| Net profit | 385 | 425 | 445 | 520 | 414 +8% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
